Join
Live feed
·
PRReleasevia Quantisnow
Sight Sciences Inc. logo

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

ByQuantisnow·Wall Street's wire, on your screen.
SGHT· Sight Sciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SGHT (Sight Sciences Inc.) and more on Quantisnow.